NXTC

NextCure, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$6.23

Price (1 Year)

$14.09 $1.64

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30
Non-compliant assets / Total market cap %60.3 / %30
Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Website

Analysis (Turkish): NXTC Hissesi Caiz mi, Helal mi? NextCure, Inc. Katılım Analizi